Conceptual framework for behavioral and social science in HIV vaccine clinical research

被引:13
作者
Lau, Chuen-Yen [1 ]
Swann, Edith M. [2 ]
Singh, Sagri [3 ,4 ]
Kafaar, Zuhayr [5 ]
Meissner, Helen I. [6 ]
Stansbury, James P. [7 ]
机构
[1] NIAID, Collaborat Clin Res Branch, Div Clin Res, NIH, Bethesda, MD 20892 USA
[2] VRP DAIDS NIAID NIH DHHS, Vaccine Clin Res Branch, Bethesda, MD 20892 USA
[3] Int AIDS Vaccine Initiat, Country Programme, New York, NY 10038 USA
[4] Int AIDS Vaccine Initiat, Reg Programme, New York, NY 10038 USA
[5] Univ Stellenbosch, Dept Psychol, ZA-7602 Matieland, South Africa
[6] NIH, Off Behav & Social Sci Res, Off Director, Bethesda, MD 20892 USA
[7] FDA CDER OND SEALD, Silver Spring, MD 20993 USA
关键词
HIV vaccine; Behavioral social science; Conceptual framework; Clinical trial; RANDOMIZED-CONTROLLED-TRIAL; DZIVE SHIRI PROJECT; SOUTH-AFRICA; STRUCTURAL INTERVENTIONS; PREVENTION INTERVENTION; EDUCATIONAL-ATTAINMENT; ECONOMIC COOPERATION; REPRODUCTIVE HEALTH; TREATMENT ADHERENCE; STEPPING STONES;
D O I
10.1016/j.vaccine.2011.07.108
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV vaccine clinical research occurs within a context where biomedical science and social issues are inter-linked. Previous HIV vaccine research has considered behavioral and social issues, but often treated them as independent of clinical research processes. Systematic attention to the intersection of behavioral and social issues within a defined clinical research framework is needed to address gaps, such as those related to participation in trials, completion of trials, and the overall research experience. Rigorous attention to these issues at project inception can inform trial design and conduct by matching research approaches to the context in which trials are to be conducted. Conducting behavioral and social sciences research concurrent with vaccine clinical research is important because it can help identify potential barriers to trial implementation, as well as ultimate acceptance and dissemination of trial results. We therefore propose a conceptual framework for behavioral and social science in HIV vaccine clinical research and use examples from the behavioral and social science literature to demonstrate how the model can facilitate identification of significant areas meriting additional exploration. Standardized use of the conceptual framework could improve HIV vaccine clinical research efficiency and relevance. Published by Elsevier Ltd.
引用
收藏
页码:7794 / 7800
页数:7
相关论文
共 82 条
  • [21] The HVTN protocol 903 vaccine preparedness study - Lessons learned in preparation for HIV vaccine efficacy trials
    Djomand, Gaston
    Metch, Barbara
    Zorrilla, Carmen D.
    Donastorg, Yeycy
    Casapia, Martin
    Villafana, Tonya
    Pape, Jean
    Figueroa, Peter
    Hansen, Marianne
    Buchbinder, Susan
    Beyrer, Chris
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (01) : 82 - 89
  • [22] Antiretroviral Therapy: A Promising HIV Prevention Strategy?
    El-Sadr, Wafaa M.
    Affrunti, Megan
    Gamble, Theresa
    Zerbe, Allison
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 : S116 - S121
  • [23] Fisher HH, 2011, AIDS BEHAV 0514
  • [24] Frew Paula M, 2009, J Health Mass Commun, V1, P11
  • [25] Understanding Differences in Enrollment Outcomes Among High-Risk Populations Recruited to a Phase IIb HIV Vaccine Trial
    Frew, Paula M.
    del Rio, Carlos
    Lu, Lu
    Clifton, Sarah
    Mulligan, Mark J.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (03) : 314 - 319
  • [26] Emerging future issues in HIV/AIDS social research
    Friedman, Samuel R.
    Kippax, Susan C.
    Phaswana-Mafuya, Nancy
    Rossi, Diana
    Newman, Christy E.
    [J]. AIDS, 2006, 20 (07) : 959 - 965
  • [27] Galea S, 2003, J URBAN HEALTH, V80, P50
  • [28] Participation in two phase II prophylactic HIV vaccine trials in the UK
    Gray, Kimberly
    Legg, K.
    Sharp, A.
    Mackie, N.
    Olarinde, F.
    De Souza, C.
    Weber, J.
    Peters, B.
    [J]. VACCINE, 2008, 26 (23) : 2919 - 2924
  • [29] Green EdwardC., 2003, RETHINKING AIDS PREV
  • [30] Guardino V., 2010, Morbidity and Mortality Weekly Report, V59, P1488